Characterization of the renal action of pranidipine in the rat

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 3, 2000, Pages 248-253

  Nagahama, Takahiko ^a   Hayashi, Koichi ^a   Fujiwara, Keiji ^a   Ozawa, Yuri ^a   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Calcium antagonist; CAS 99522 79 9; Pranidipine; Rat; Renal microvascular effect

Indexed keywords

CALCIUM ANTAGONIST; PRANIDIPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HYDRONEPHROSIS; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; MICROVASCULATURE; NONHUMAN; PROTEINURIA; RAT;

EID: 0034121431     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300194     Document Type: Article

References (34)

1. [1] Anderson, S., Rennke, H. G., Brenner, B. M., Therapeutic advantage of converting enzyme inhibitor in progressive renal disease associated with systemic hypertension in the rats. J. Clin. Invest. 77, 1993 (1986)
2. [2] Lewis, E. J., Hunsicker, L. G., Bain, R. P. et al., The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl. J. Med. 329, 1456 (1993)
3. [3] The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349, 1857 (1997)
4. [4] Emile, R., Leif, C., Jalal, K. et al., Role of cytokines in the mechanism of action of amlodipine: The PRAISE Heart Failure Trial. J. Am. Coll. Cardiol. 30, 35 (1997)
5. [5] Katsumata, H., Suzuki, H., Ohishi, A. et al., Effects of antihypertensive agents on blood pressure and the progress of renal failue in partially nephrectomized spontaneously hypertensive rats. Lab. Invest. 62, 474 (1990)
6. [6] Patrizio, T., Riccardo, G., Marco, P. et al., Outcome results of the fosinopril versus amlodipine cardiovascular events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21, 597 (1998)
7. [7] Schrrier, W., Estacio, R. O., Jeffers, B., Appropriate blood pressure control in NIDDM (ABCD) Trial. Diabetologia 39, 1646 (1996)
8. [8] Tolins, J. P., Raij, L., Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16, 452 (1990)
9. [9] Hayashi, K., Nagahama, T., Oka, K. et al., Disparate effects of calcium antagonists on renal microcirculation. Hypertens. Res. 19, 31 (1996)
10. [10] Saruta, T., Kanno, Y., Hayashi, K. et al., Antihypertensive agents and renal protection: calcium channel blockers. Kidney Int. 49 (Suppl. 55), S52 (1996)
11. [11] Loutzenhiser, R., Hayashi, K., Epstein, M., Calcium antagonists augment glomerular filtration rate of angiotensin II-vasoconstricted isolated perfused rat kidneys by dilating afferent but not efferent arterioles. J. Cardiovasc. Pharmacol. 12 (Suppl. 6), S144 (1988)
12. [12] Carmines, P. K., Navar, L. G., Disparate effects of Ca Channel blockade on afferent and efferent arteriolar responses to ANG II. Am. J. Physiol. 256, F677 (1989)
13. [13] Fleming, J. T., Parekh, N., Steinhausen, M., Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am. J. Physiol. 253, F1157 (1987)
14. [14] Yotsumoto, T., Masuda, Y., Shudo, C. et al., Effects of efonidipine hydrochloride (NZ-105), a calcium antagonist, on renal function in conscious spontaneously hypertensive rats. Gen. Pharmacol. 25, 333 (1995)
15. rd International Congress of Nephrology, Madrid/Spain (1996)
16. [16] Arima, S., Ito, S., Omata, K. et al., Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int. 49 (Suppl. 55), S132 (1996)
17. [17] Fujiwara, K., Hayashi, K., Kanno, Y. et al., Renal protective effects of efonidipine hydrochloride in subtotally nephrectomized spontaneously hypertensive rats. Clin. Exp. Hypertens. 20, 295 (1998)
18. [18] Kanno, Y., Suzuki, H. Okada, H. et al., Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J. Cardiovasc. Pharmacol. 23, 480 (1994)
19. [19] Okada, H., Suzuki, H., Kanno, Y. et al., Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 26, 564 (1995)
20. [20] Loutzenhiser, R., Hayashi, K., Epstein, M., Atrial natriuretic peptide reverses afferent arteriolar vasoconstriction and potentiates efferent arteriolar vasoconstriction in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. 246, 522 (1988)
21. [21] Loutzenhiser, R., Hayashi, K., Epstein, M., Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am. J. Physiol. 257, F561 (1989)
22. [22] Steinhausen, M., Snoei, H., Parekh, N. et al., Hydronephrosis: A new method to visualize vas afferens, efferens, and glomerular network. Kidney Int. 23, 794 (1983)
23. [23] Feiner, H. D., Cabili, S., Baldwin, D. S. et al., Intrarenal vascular sclerosis in IgA nephropathy. Clin. Nephrol. 18, 183 (1982)
24. [24] Okada, H., Suzuki, H., Konishi, K. et al., Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy. Clin. Nephrol. 37, 235 (1992)
25. [25] Hostetter, T. H., Olson, J. L., Rennke, H. G. et al., Hyperfiltration in remnant nephrons; a potentially adverse response to renal ablation. Am. J. Physiol. 241, F85 (1981)
26. [26] Anderson, S., Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension 17, 288 (1991)
27. [27] Nakayama, N., Ikezono, K., Fujio, N. et al., OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist. Cardiovasc. Drug Rev. 9, 147 (1991)
28. 2+ channel antagonist, in rats: comparison with nifedipine and amlodipine. Eur. J. Pharmacol. 324, 201 (1997)
29. [29] Uehara, Y., Kawabata, Y., Ohshima, N. et al., New dihydropyridine calcium channel antagonist, pranidipine, attenuates hypertensive renal injury in Dahl salt-sensitive rats. J. Cardiovasc. Pharmacol. 23, 970 (1994)
30. [30] Mori, T., Takeuchi, T., Ohura, M. et al., Pranidipine, a new 1,4-dihydropyridine calcium channel blocker enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Molec. Cell. Biochem. 178, 335 (1998)
31. [31] Dworkin, L. D., Benstein, J. A., Parker, M. et al., Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int. 43, 808 (1993)
32. [32] Harris, D. C. H., Hammond, W. S., Burke, T. J. et al., Verapamil protects against progression of experimental chronic renal failure. Kidney Int. 31, 41 (1987)
33. [33] Farber, J. L., The role of calcium in cell death. Life Sci. 29, 1289 (1981)
34. [34] McCord, J. M., Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312, 159 (1985)